147 related articles for article (PubMed ID: 14767986)
1. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
Cammà C; Di Bona D; Schepis F; Heathcote EJ; Zeuzem S; Pockros PJ; Marcellin P; Balart L; Alberti A; Craxì A
Hepatology; 2004 Feb; 39(2):333-42. PubMed ID: 14767986
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alfa-2a in patients with chronic hepatitis C.
Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials.
Chalasani N; Manzarbeitia C; Ferenci P; Vogel W; Fontana RJ; Voigt M; Riely C; Martin P; Teperman L; Jiao J; Lopez-Talavera JC;
Hepatology; 2005 Feb; 41(2):289-98. PubMed ID: 15660392
[TBL] [Abstract][Full Text] [Related]
6. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis.
Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ
Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570
[TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.
Lindsay KL; Trepo C; Heintges T; Shiffman ML; Gordon SC; Hoefs JC; Schiff ER; Goodman ZD; Laughlin M; Yao R; Albrecht JK;
Hepatology; 2001 Aug; 34(2):395-403. PubMed ID: 11481625
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
11. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.
Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML
Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
Ferenci P
Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
[TBL] [Abstract][Full Text] [Related]
14. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
16. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
Silva M; Poo J; Wagner F; Jackson M; Cutler D; Grace M; Bordens R; Cullen C; Harvey J; Laughlin M
J Hepatol; 2006 Aug; 45(2):204-13. PubMed ID: 16780997
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
Hornberger J; Torriani FJ; Dieterich DT; Bräu N; Sulkowski MS; Torres MR; Green J; Patel K
J Clin Virol; 2006 Aug; 36(4):283-91. PubMed ID: 16765638
[TBL] [Abstract][Full Text] [Related]
20. The follow-up of the efficacy of antiviral therapy at patients with chronic hepatitis C.
Vere CC; Avrămescu C; Mogoantă L; Rogoveanu I; Cazacu S; Ciurea T
Rom J Morphol Embryol; 2005; 46(3):175-8. PubMed ID: 16444301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]